![](/img/cover-not-exists.png)
Intermittent schedules of the oral RAFâMEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Guo, Christina, Chénard-Poirier, Maxime, Roda, Desamparados, de Miguel, Maria, Harris, Samuel J, Candilejo, Irene Moreno, Sriskandarajah, Priya, Xu, Wen, Scaranti, Mariana, Constantinidou, Anastasia,Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(20)30464-2
Date:
October, 2020
File:
PDF, 1.23 MB
2020